Target type: biologicalprocess
The cell fate determination process in which a cell becomes capable of differentiating autonomously into a mesoderm cell regardless of its environment; upon determination, the cell fate cannot be reversed. [GOC:go_curators, ISBN:0878932437]
Mesodermal cell fate determination is a complex and highly regulated process that orchestrates the development of a diverse array of tissues and organs from the mesoderm, one of the three primary germ layers in early embryos. This process involves a intricate interplay of signaling pathways, transcription factors, and epigenetic modifications, culminating in the precise specification of distinct cell fates.
The mesoderm arises from a population of pluripotent cells, capable of differentiating into a wide range of cell types. During gastrulation, a critical stage of embryonic development, these cells undergo a series of movements and rearrangements, ultimately forming the mesodermal germ layer. Once established, the mesoderm is subdivided into distinct regions, each with a unique developmental potential. These regions are defined by the expression of specific signaling molecules and transcription factors.
One of the key signaling pathways involved in mesodermal cell fate determination is the Wnt pathway. Wnt signals, secreted proteins, play a crucial role in patterning the mesoderm along the anterior-posterior axis, influencing the development of different mesodermal structures. For instance, Wnt signaling gradients contribute to the formation of the somites, segmented blocks of mesoderm that give rise to the vertebrae, muscles, and dermis.
Another essential signaling pathway is the transforming growth factor beta (TGF-β) pathway. TGF-β signaling is implicated in the development of various mesodermal lineages, including blood, heart, and kidney. For example, TGF-β signaling is essential for the specification of hematopoietic progenitors, cells that give rise to all blood cell types.
Transcription factors, proteins that bind to DNA and regulate gene expression, are critical for executing specific cell fates within the mesoderm. For instance, the transcription factor Pax6 is essential for the development of the eye, a mesodermal-derived structure. In addition, the transcription factor GATA4 plays a key role in heart development.
Epigenetic modifications, changes in DNA structure that do not alter the underlying DNA sequence, also contribute to mesodermal cell fate determination. These modifications can include DNA methylation and histone modifications, which influence gene expression patterns. For example, specific methylation patterns in the mesoderm are associated with the activation of genes involved in muscle development.
Mesodermal cell fate determination is a dynamic process that involves a complex interplay of multiple signaling pathways, transcription factors, and epigenetic modifications. This intricate regulatory network ensures the precise specification of a wide array of mesodermal cell types, ultimately giving rise to the diverse tissues and organs essential for animal development and function.'
"
Protein | Definition | Taxonomy |
---|---|---|
Bone morphogenetic protein 4 | A bone morphogenetic protein 4 that is encoded in the genome of human. [PRO:CNA, UniProtKB:P12644] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
dorsomorphin | dorsomorphin : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3 and 6 by pyridin-4-yl and p-[2-(piperidin-1-yl)ethoxy]phenyl groups, respectively. It is a potent, selective, reversible, and ATP-competitive inhibitor of AMPK (AMP-activated protein kinase, EC 2.7.11.31) and a selective inhibitor of bone morphogenetic protein (BMP) signaling. dorsomorphin: an AMPK inhibitor | aromatic ether; piperidines; pyrazolopyrimidine; pyridines | bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor |
ldn 193189 | LDN 193189: inhibits bone morphogenetic protein signaling | pyrimidines | |
ml347 | ML347: an ALK2 inhibitor; structure in first source |